PFE — PFIZER INC

NYSE · Health Care · Pharmaceuticals · CIK 78003 ·
Last close
$26.31
Market Cap
$149.96B
52W High
$27.20
52W Low
$23.21
ADV30
41,671,301
Next earnings
2026-11-03
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 15,034,000,000 10,942,000,000 3,537,000,000 -248,000,000 201,131,000,000 976,000,000 115,639,000,000
Mar 2026 14,450,000,000 10,902,000,000 4,131,000,000 2,687,000,000 207,618,000,000 1,703,000,000 117,214,000,000
Dec 2025 17,557,000,000 12,285,000,000 3,475,000,000 -1,648,000,000 208,160,000,000 1,142,000,000 121,385,000,000
Sep 2025 16,654,000,000 12,482,000,000 4,137,000,000 3,541,000,000 208,731,000,000 1,343,000,000 115,635,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$13,403,000,000
Investing CF
$-5,683,000,000
Financing CF
$-8,399,000,000
CapEx
$-2,416,000,000
Dividends Paid
$-9,785,000,000
Buybacks
EPS Diluted TTM
$0.76
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$112,087,000,000
Inventory
$9,945,000,000
Receivables
$16,192,000,000
ST Investments
$10,722,000,000
EBIT TTM
$6,907,000,000
Pretax Income TTM
$4,209,000,000
Interest Exp TTM
$2,698,000,000
Analysts
26

Yahoo Snapshot (yfinance, live)

Total Revenue
$63,695,998,976
EBITDA
$25,383,000,064
Free Cash Flow
$12,485,624,832
Enterprise Value
$202,036,412,416
Total Cash
$11,704,000,512
Total Debt
$63,480,000,512
Shares Out
5,699,673,589
Trailing EPS
$0.75
Book Value
$14.95
ROE
5.0%
ROA
5.8%
Div Yield
6.46%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 62,579,000,000 17,407,000,000 7,771,000,000 208,160,000,000 121,385,000,000 11,704,000,000
Dec 2024 63,627,000,000 14,938,000,000 8,031,000,000 213,396,000,000 124,899,000,000 12,744,000,000
Dec 2023 59,554,000,000 4,417,000,000 2,119,000,000 226,501,000,000 137,213,000,000 8,700,000,000
Dec 2022 101,175,000,000 38,117,000,000 31,372,000,000 197,205,000,000 101,289,000,000 29,267,000,000

TTM Snapshot

Revenues TTM
$77,866,000,000
NetIncome TTM
$18,837,000,000
OpCashFlow TTM
$0
Assets (Latest)
$213,396,000,000
Forward EPS
$2.89

Max Pain — expiry 2026-08-21

max pain strike: $25.00 · spot: $26.80 · call oi: 173,853 · put oi: 208,660
Expected Move to 2026-08-21: ±$0.56 (2.09%) — implied range $26.24$27.36 · ATM straddle on $27.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NVO NOVO NORDISK A S $153.38B $46.39
NONOF NOVO NORDISK A S $143.36B $43.36
VRTX VERTEX PHARMACEUTICALS INC / MA $133.17B $525.73
BMY BRISTOL MYERS SQUIBB CO $130.12B $63.70
ABT ABBOTT LABORATORIES $193.18B $110.91

News headlines (Yahoo Finance, 1h cache)

How Pfizer’s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story
2026-08-13 15:12 · Yahoo
5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call
2026-08-13 02:29 · Yahoo
Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?
2026-08-12 15:03 · Yahoo
Gene Therapy Remains Top-of-Mind in Hemophilia Despite Recent Market Contraction, as Physicians and Patients Raise the Bar for Success
2026-08-13 18:59 · Yahoo
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...
2026-08-13 05:01 · Yahoo
Valneva Q2 Earnings Call Highlights
2026-08-13 19:04 · Yahoo
The Sharpest Exchanges From ABBV's Earnings Call
2026-08-13 16:10 · Yahoo
The Advertising Research Foundation Announces 2026 ARF David Ogilvy Awards Finalists
2026-08-13 15:02 · Yahoo
Pfizer CEO Buys $1 Million of Stock
2026-08-13 12:20 · Yahoo
This Healthcare Services Stock Has 37% Upside
2026-08-13 12:01 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-08-12 16:04:39 2026-08-12 Bourla Albert COB, CEO P - Purchase 26.34 38000 1000920